Special Issue

Role of Matrix Metalloproteinase in Diseases

Message from the Guest Editor

Matrix metalloproteinases are enzymes that degrade the extracellular matrix, including collagen, elastin, and fibronectin, and their enzymatic actions are deeply involved in promoting the infiltration of inflammatory cells and the progression of fibrosis. Augmentation of these enzymes has been observed in various diseases, including vascular, heart, lung, liver, and kidney diseases, and the inhibition of these enzymes is expected to prevent and treat various diseases. Matrix metalloproteinases are expressed as their proforms which are activated by enzymes such as elastase and chymase, and the enhancement or inhibition of process also plays an important role in the regulation of matrix metalloproteinases, resulting in the involvement of various diseases. In this Special Issue, we are looking for a wide range of matrix metalloproteinase-related diseases.

Guest Editor

Prof. Dr. Shinji Takai
Department of Innovative Medicine, Graduate School of Medicine, Osaka Medical College, Takatsuki, Japan

Deadline for manuscript submissions

closed (31 August 2022)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/67078

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).